Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Thomas Coudry
  • Thomas Coudry
VIV VIVENDI (Media)

VIVENDI - NEUTRAL | EUR29.3(-10%) Full takeover might not be the best ...

VIVENDI - NEUTRAL | EUR29.3(-10%) Full takeover might not be the best scenario Buy out of Amber’s stake leads to possible takeover More than decent price, yet premium not overwhelming The interest of a full takeover at this price is not obvious Synergies potential limited with Travel retail as a burden

Victor Floc’h
  • Victor Floc’h
ALSEN SENSORION SA (Health Care)

SENSORION - CORPORATE | EUR6(+192%) Sensorion and Sonova sign strategi...

SENSORION - CORPORATE | EUR6(+192%) Sensorion and Sonova sign strategic research collaboration A multi-year strategic collaboration A natural history study at the heart of this partnership A NHS provides critical information for rare and orphan diseases Once again confirms Sensorion’s leadership in hearing loss

Cedric Rossi
  • Cedric Rossi

INDITEX: H1 2021 results: Top line is recovering a bit faster than mar...

INDITEX - BUY | EUR33(+12%) H1 2021 results: Top line is recovering a bit faster than margins Q2 sales matched CS forecasts: a good top-line recovery Q2 GM and EBIT a touch shy of CS expectations Declining inventory levels towards healthier levels Encouraging current trading: sales between 1st Aug – 9th Sep: +22%

Dylan Van Haaften
  • Dylan Van Haaften
ABVX ABIVAX SA (Health Care)

ABIVAX (BUY, TP EUR53) | ABX464 UC PhIIb complete dataset further diff...

ABIVAX (BUY, TP EUR53) | ABX464 UC PhIIb complete dataset further differentiates vs JAKi

Thomas Coudry
  • Thomas Coudry
COP Compugroup Medi... (Technology)

COMPUGROUP MEDICAL (NEUTRAL, TP EUR87) | 2023 and 2025 EBITDA guidance...

COMPUGROUP MEDICAL (NEUTRAL, TP EUR87) | 2023 and 2025 EBITDA guidance a touch above consensus

Thomas Coudry
  • Thomas Coudry
VIV VIVENDI (Media)

VIVENDI - NEUTRAL | EUR29.3(-10%) Full takeover might not be the best ...

VIVENDI - NEUTRAL | EUR29.3(-10%) Full takeover might not be the best scenario Buy out of Amber’s stake leads to possible takeover More than decent price, yet premium not overwhelming The interest of a full takeover at this price is not obvious Synergies potential limited with Travel retail as a burden

Victor Floc’h
  • Victor Floc’h
ALSEN SENSORION SA (Health Care)

SENSORION - CORPORATE | EUR6(+192%) Sensorion and Sonova sign strategi...

SENSORION - CORPORATE | EUR6(+192%) Sensorion and Sonova sign strategic research collaboration A multi-year strategic collaboration A natural history study at the heart of this partnership A NHS provides critical information for rare and orphan diseases Once again confirms Sensorion’s leadership in hearing loss

Cedric Rossi
  • Cedric Rossi

INDITEX: H1 2021 results: Top line is recovering a bit faster than mar...

INDITEX - BUY | EUR33(+12%) H1 2021 results: Top line is recovering a bit faster than margins Q2 sales matched CS forecasts: a good top-line recovery Q2 GM and EBIT a touch shy of CS expectations Declining inventory levels towards healthier levels Encouraging current trading: sales between 1st Aug – 9th Sep: +22%

Dylan Van Haaften
  • Dylan Van Haaften
ABVX ABIVAX SA (Health Care)

ABIVAX (BUY, TP EUR53) | ABX464 UC PhIIb complete dataset further diff...

ABIVAX (BUY, TP EUR53) | ABX464 UC PhIIb complete dataset further differentiates vs JAKi

Thomas Coudry
  • Thomas Coudry
COP Compugroup Medi... (Technology)

COMPUGROUP MEDICAL (NEUTRAL, TP EUR87) | 2023 and 2025 EBITDA guidance...

COMPUGROUP MEDICAL (NEUTRAL, TP EUR87) | 2023 and 2025 EBITDA guidance a touch above consensus

Thomas Coudry
  • Thomas Coudry
VIV VIVENDI (Media)

VIVENDI - NEUTRAL | EUR29.3(-10%) Full takeover might not be the best ...

VIVENDI - NEUTRAL | EUR29.3(-10%) Full takeover might not be the best scenario Buy out of Amber’s stake leads to possible takeover More than decent price, yet premium not overwhelming The interest of a full takeover at this price is not obvious Synergies potential limited with Travel retail as a burden

Victor Floc’h
  • Victor Floc’h
ALSEN SENSORION SA (Health Care)

SENSORION - CORPORATE | EUR6(+192%) Sensorion and Sonova sign strategi...

SENSORION - CORPORATE | EUR6(+192%) Sensorion and Sonova sign strategic research collaboration A multi-year strategic collaboration A natural history study at the heart of this partnership A NHS provides critical information for rare and orphan diseases Once again confirms Sensorion’s leadership in hearing loss

Cedric Rossi
  • Cedric Rossi

INDITEX: H1 2021 results: Top line is recovering a bit faster than mar...

INDITEX - BUY | EUR33(+12%) H1 2021 results: Top line is recovering a bit faster than margins Q2 sales matched CS forecasts: a good top-line recovery Q2 GM and EBIT a touch shy of CS expectations Declining inventory levels towards healthier levels Encouraging current trading: sales between 1st Aug – 9th Sep: +22%

Dylan Van Haaften
  • Dylan Van Haaften
ABVX ABIVAX SA (Health Care)

ABIVAX (BUY, TP EUR53) | ABX464 UC PhIIb complete dataset further diff...

ABIVAX (BUY, TP EUR53) | ABX464 UC PhIIb complete dataset further differentiates vs JAKi

Thomas Coudry
  • Thomas Coudry
COP Compugroup Medi... (Technology)

COMPUGROUP MEDICAL (NEUTRAL, TP EUR87) | 2023 and 2025 EBITDA guidance...

COMPUGROUP MEDICAL (NEUTRAL, TP EUR87) | 2023 and 2025 EBITDA guidance a touch above consensus

Thomas Coudry
  • Thomas Coudry
VIV VIVENDI (Media)

VIVENDI - NEUTRAL | EUR29.3(-10%) Full takeover might not be the best ...

VIVENDI - NEUTRAL | EUR29.3(-10%) Full takeover might not be the best scenario Buy out of Amber’s stake leads to possible takeover More than decent price, yet premium not overwhelming The interest of a full takeover at this price is not obvious Synergies potential limited with Travel retail as a burden

Victor Floc’h
  • Victor Floc’h
ALSEN SENSORION SA (Health Care)

SENSORION - CORPORATE | EUR6(+192%) Sensorion and Sonova sign strategi...

SENSORION - CORPORATE | EUR6(+192%) Sensorion and Sonova sign strategic research collaboration A multi-year strategic collaboration A natural history study at the heart of this partnership A NHS provides critical information for rare and orphan diseases Once again confirms Sensorion’s leadership in hearing loss

Cedric Rossi
  • Cedric Rossi

INDITEX: H1 2021 results: Top line is recovering a bit faster than mar...

INDITEX - BUY | EUR33(+12%) H1 2021 results: Top line is recovering a bit faster than margins Q2 sales matched CS forecasts: a good top-line recovery Q2 GM and EBIT a touch shy of CS expectations Declining inventory levels towards healthier levels Encouraging current trading: sales between 1st Aug – 9th Sep: +22%

Dylan Van Haaften
  • Dylan Van Haaften
ABVX ABIVAX SA (Health Care)

ABIVAX (BUY, TP EUR53) | ABX464 UC PhIIb complete dataset further diff...

ABIVAX (BUY, TP EUR53) | ABX464 UC PhIIb complete dataset further differentiates vs JAKi

Thomas Coudry
  • Thomas Coudry
COP Compugroup Medi... (Technology)

COMPUGROUP MEDICAL (NEUTRAL, TP EUR87) | 2023 and 2025 EBITDA guidance...

COMPUGROUP MEDICAL (NEUTRAL, TP EUR87) | 2023 and 2025 EBITDA guidance a touch above consensus

ResearchPool Subscriptions

Get the most out of your insights

Get in touch